Shalby Ltd Q1 FY27 Results: Revenue Grows 11.6%, PAT Rises to ₹10.5 Crore

Consolidated Revenue: ₹338.6 crore (+11.6% YoY)
Consolidated PAT: ₹10.5 crore (+36.4% YoY)

Reader Takeaway: Revenue growth is strong, but margin pressure from investments needs to ease for targets.

What just happened

Shalby Ltd announced its Q1 FY2027 results, posting a consolidated revenue of ₹338.6 crore, an 11.6% increase compared to the same period last year. Consolidated Profit After Tax (PAT) rose to ₹10.5 crore, up from ₹7.7 crore in Q1 FY26. The company's consolidated EBITDA was ₹49 crore, showing a marginal 1% year-on-year growth, with EBITDA margins at 14.5%, down from 16% in the prior year's quarter. A key operational highlight was the Gurgaon unit achieving EBITDA break-even for the first time.

Why this matters

The revenue growth indicates continued demand for Shalby's healthcare services. The rise in PAT is a positive sign for profitability. The achievement of EBITDA break-even at the Gurgaon unit is a significant operational milestone that could contribute positively to future earnings. However, the dip in EBITDA margins warrants attention as it stems from strategic investments.

The backstory

Shalby Ltd is a leading healthcare group with a significant presence in multi-specialty hospital operations and medical device manufacturing (MedTech). The company has been focusing on expanding its hospital network and improving its MedTech segment's performance. Recent strategic moves include integrating acquired facilities and optimizing operations across its various units.

What changes now

Management expressed confidence in future margin expansion, targeting up to 20% EBITDA margin for the full year, driven by revenue growth from new TPA renewals, improving performance of units like Gurgaon, and the MedTech segment.

Risks to watch

Key concerns include the sustainability of margin expansion to reach the 20% target, given the current pressure from operational investments and doctor recruitment. The increasing exposure to government business schemes (now 32%) could impact the cash conversion cycle. Additionally, a recent downgrade in ICRA's long-term credit rating for a significant facility from (A+) to (A), though with a stable outlook, requires monitoring.

Peer comparison

Shalby operates in the healthcare sector, competing with other hospital chains and medical device manufacturers. Companies like Fortis Healthcare, Apollo Hospitals, and Max Healthcare are major players in the hospital segment, while companies like Poly Medicure and Sahajanand Medical Technologies operate in the medical devices space.

Context metrics (time-bound)

• Consolidated Revenue (Q1 FY27): ₹338.6 crore (+11.6% YoY)
• Consolidated EBITDA (Q1 FY27): ₹49 crore (+1% YoY)
• EBITDA Margin (Q1 FY27): 14.5% (vs 16% in Q1 FY26)
• Consolidated PAT (Q1 FY27): ₹10.5 crore (vs ₹7.7 crore in Q1 FY26)
• Gurgaon Unit: Achieved EBITDA break-even.
• Transplants (Q1 FY27): 47 (41 kidney, 5 liver, 1 bone marrow).
• Government Business Mix: Increased to 32% from 24% YoY.
• Credit Rating: Long-term facility rating downgraded from (A+) to (A) by ICRA, outlook stable.

What to track next

Investors will be closely watching Shalby's ability to improve EBITDA margins towards the 20% target. Monitoring the cash conversion cycle and receivable days, especially with the growing proportion of government business, will be crucial. The successful integration and performance improvement of newer units like Gurgaon and the MedTech segment's margin trajectory are also key areas to track.